FDA Letter Says Alkermes, J&J's Risperdal Consta Not Approvable

Alkermes Inc.'s stock plunged 67.8 percent Monday after its partner, Janssen Pharmaceutica Products LP, said the FDA issued a non-approvable letter for Risperdal Consta, a twice-monthly injectable form of the anti-psychotic drug Risperdal. (BioWorld Today)